MyFinsight
Home
Blog
About
Net increase in
cash, cash...
-$85,376K
(-575.92%↓ Y/Y)
Stock-based compensation
expense
$2,149K
(-41.32%↓ Y/Y)
Prepaid expenses and
other current assets
-$187K
(96.12%↑ Y/Y)
Depreciation expense
$62K
(-64.57%↓ Y/Y)
Other assets
-$24K
(31.43%↑ Y/Y)
Maturities of marketable
securities
$22,500K
(-80.18%↓ Y/Y)
Net cash used in
operating activities
-$44,030K
(4.12%↑ Y/Y)
Net cash provided by
(used in) investing...
-$40,911K
(-222.89%↓ Y/Y)
Net cash provided by
financing activities
-$435K
Canceled cashflow
$2,422K
Canceled cashflow
$22,500K
Other income, net
$1,569K
Net loss
-$32,782K
(40.89%↑ Y/Y)
Accrued expenses
-$12,756K
(-2763.05%↓ Y/Y)
Purchases of marketable
securities
$63,281K
(-21.04%↓ Y/Y)
Proceeds from issuance of
equity securities
-$435K
Canceled cashflow
$1,569K
Accounts payable
-$557K
(-132.35%↓ Y/Y)
Amortization of premium on
marketable securities
-$345K
(71.63%↑ Y/Y)
Lease expense
-$12K
(90.98%↑ Y/Y)
Purchases of property and
equipment
$130K
(91.18%↑ Y/Y)
Operating expenses
$34,351K
Back
Back
Cash Flow
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)
source: myfinsight.com